Search

Your search keyword '"Kassouf W"' showing total 664 results
Start Over Author "Kassouf W"
664 results on '"Kassouf W"'

1. Development and external validation of an artificial intelligence-based tool for PROGression Risk assessment in Non-muscle invasive Bladder Cancer (PROGRxN-BCa)

Author

Kwong, J., primary, Al-Daqqaq, Z., additional, Chelliahpillai, Y., additional, Lee, S., additional, Kim, K., additional, Ringa, M., additional, Ali, A., additional, Feifer, A., additional, Wettstein, M., additional, Kassouf, W., additional, Black, P.C., additional, Breau, R.H., additional, Lodde, M., additional, Fairey, A., additional, Lattouf, J-B., additional, Jeldres, C., additional, Rendon, R., additional, Alimohamed, N., additional, Chung, P., additional, Fleshner, N.E., additional, Finelli, A., additional, Zlotta, A.R., additional, Johnson, A.E.W., additional, and Kulkarni, G.S., additional

Published
2024
Full Text
View/download PDF

3. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium

Author

Mir, Maria Carmen, Marchioni, Michele, Zargar, Homi, Zargar-Shoshtari, K., Fairey, A.S., Mertens, Laura S., Dinney, C.P., Krabbe, L.M., Cookson, M.S., Jacobsen, N.E., Griffin, J., Montgomery, J.S., Vasdev, N., Yu, E.Y., Xylinas, E., McGrath, J.S., Kassouf, W., Dall'Era, M.A., Sridhar, S.S., Aning, J., Shariat, S.F., Wright, J.L., Thorpe, A.C., Morgan, T.M., Holzbeierlein, J.M., Bivalacqua, T.J., North, S., Barocas, D.A., Lotan, Y., Grivas, P., Stephenson, A.J., Shah, J.B., van Rhijn, B.W., Spiess, P.E., Daneshmand, D., and Black, P.C.

Published
2021
Full Text
View/download PDF

4. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Author

Vasdev, N., Zargar, H., Noël, J. P., Veeratterapillay, R., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Gandhi, N. M., Griffin, J., Montgomery, J. S., Yu, E. Y., Xylinas, E., Campain, N. J., Kassouf, W., Dall’Era, M. A., Seah, J. A., Ercole, C. E., Horenblas, S., Sridhar, S. S., McGrath, J. S., Aning, J., Shariat, S. F., Wright, J. L., Morgan, T. M., Bivalacqua, T. J., North, S., Barocas, D. A., Lotan, Y., Grivas, P., Stephenson, A. J., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Spiess, P. E., Holzbeierlein, J. M., Thorpe, A., and Black, P. C.

Published
2019
Full Text
View/download PDF

5. Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: An inverse probability treatment weighted analysis

Author

Marcq, G., primary, Kool, R., additional, Dragomir, A., additional, Kulkarni, G.S., additional, Breau, R.H., additional, Kim, M., additional, Busca, I., additional, Abdi, H., additional, Dawidek, M., additional, Uy, M., additional, Fervaha, G., additional, Cury, F.L., additional, Alimohamed, N., additional, Izawa, J., additional, Jeldres, C., additional, Rendon, R., additional, Shayegan, B., additional, Siemens, R., additional, Black, P.C., additional, and Kassouf, W., additional

Published
2023
Full Text
View/download PDF

6. Résultats oncologiques des patients présentant une atteinte ganglionnaire à la suite d’une chimiothérapie néoadjuvante et d’une cystectomie totale pour un cancer de la vessie infiltrant le muscle : une étude observationnelle multicentrique du groupe de travail sur le carcinome urothélial de l’eau young academic urologists (YAU)

Author

Marcq, G., primary, Kassouf, W., additional, Roumiguié, M., additional, Pradere, B., additional, Beauval, J., additional, Xylinas, E., additional, Pouessel, D., additional, Sargos, P., additional, and Ploussard, G., additional

Published
2022
Full Text
View/download PDF

7. Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54]

Author

Mir, Maria Carmen, primary, Marchioni, Michele, additional, Zargar, Homi, additional, Zargar-Shoshtari, K., additional, Fairey, A.S., additional, Mertens, Laura S., additional, Dinney, C.P., additional, Krabbe, L.M., additional, Cookson, M.S., additional, Jacobsen, N.E., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Xylinas, E., additional, McGrath, J.S., additional, Kassouf, W., additional, Dall'Era, M.A., additional, Sridhar, S.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A.J., additional, Shah, J.B., additional, van Rhijn, B.W., additional, Spiess, P.E., additional, Daneshmand, S., additional, and Black, P.C., additional

Published
2022
Full Text
View/download PDF

11. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer

Author

Roumiguie, M, Kamat, AM, Bivalacqua, TJ, Lerner, SP, Kassouf, W, Bohle, A, Brausi, M, Buckley, R, Persad, R, Colombel, M, Lamm, D, Palou-Redorta, J, Soloway, M, Brothers, K, Steinberg, G, Lotan, Y, Sylvester, R, Witjes, JA, and Black, PC

Subjects
Clinical trials, Non-muscle-invasive bladder cancer, Intravesical therapy, Bacillus Calmette-Guerin, Risk stratification
Abstract

Context: A large proportion of patients with non-muscle-invasive bladder cancer (NMIBC) fall in the gap between bacillus Calmette-Guerin (BCG)-naive and BCG-unresponsive disease. As multiple therapeutic agents move into this gray area, there is a critical need to define the disease state and establish recommendations for optimal trial design. Objective: To develop a consensus on optimal trial design for patients with BCG-exposed NMIBC, defined as high-grade recurrence after BCG treatment that does not meet the criteria for BCG-unresponsive disease. Evidence acquisition: We conducted a literature review using the Cochrane Library, Medline, and Embase and a review of clinical trials in ClinicalTrials.gov as a basis to generate consensus recommendations for clinical trial design in BCG-exposed NMIBC. Evidence synthesis: BCG-exposed NMIBC encompasses BCG resistance (presence of high-grade Ta or carcinoma in situ [CIS] at 3-mo evaluation after induction BCG) and delayed relapse. Randomized controlled trials are required to compare experimental therapies to a control arm receiving additional BCG, although ongoing BCG shortages may impact our ability to follow an optimal trial design. A placebo should be used in combination with BCG if the treatment arm includes BCG plus a study drug. Trials will either need to separate patients with and without CIS into two cohorts, or stratify by the presence of CIS at the time of randomization. If two cohorts are used, the primary endpoint for CIS patients should be complete response within a predetermined time. The primary endpoint in a cohort with Ta/T1 only, or if a single combined cohort is used, should be the duration of event-free survival. Suggested efficacy thresholds and corresponding sample sizes are provided. Conclusions: The International Bladder Cancer Group has developed recommendations regarding definitions, endpoints, and clinical trial design for BCG-exposed NMIBC to encourage uniformity among studies in this disease state. Patient summary: Our consensus provides a precise definition of the disease state for bladder cancer not invading the bladder muscle and exposed to bacillus Calmette-Guerin (BCG) treatment. Clear guidance for conducting optimal clinical trials in this disease setting was established and we believe that this will promote further progress in this field. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Published
2022

12. Impact de la récidive locale et métastatique sur la survie des patients traités par cystectomie totale ayant des marges chirurgicales positives sur les tissus mous

Author

Lainé-caroff, P., primary, Ouzaïd, I., additional, Moschini, M., additional, Hendricksen, K., additional, Kassouf, W., additional, Baumann, B., additional, Noon, A., additional, Ploussard, G., additional, Necchi, A., additional, Hermieu, J., additional, Sargos, P., additional, and Xylinas, E., additional

Published
2021
Full Text
View/download PDF

15. Novel classification for upper tract urothelial carcinoma to better risk-stratify patients eligible for kidney sparing strategies: an international collaborative study

Author

Marcq, G., primary, Foerster, B., additional, Matin, S.F., additional, Spiess, P., additional, Bivalacqua, T., additional, Wu, W., additional, Rouprêt, M., additional, Krabbe, L.M., additional, Xylinas, E., additional, Mir, C., additional, Hendricksen, K., additional, Mari, A., additional, Egawa, S., additional, Briganti, A., additional, Moschini, M., additional, Mathieu, R., additional, Ku, J.H., additional, Autorino, R., additional, Heidenreich, A., additional, Chlosta, P., additional, Joniau, S., additional, Pycha, A., additional, D’andrea, D., additional, Shariat, S.F., additional, Kassouf, W., additional, and Wu, Wen-Jeng, additional

Published
2021
Full Text
View/download PDF

17. Bénéfice de l’irradiation ganglionnaire pour les patients atteints d’un cancer de la vessie infiltrant le muscle : analyse par score de propension d’une cohorte multicentrique

Author

Marcq, G., Kool, R., Dragomir, A., Kulkarni, G.S., Breau, R.H., Kim, M., Busca, I., Abdi, H., Dawidek, M., Uy, M., Fervaha, G., Alimohamed, N., Izawa, J., Jeldres, C., Ricardo, R., Shayegan, B., Siemens, R., Black, P.C., Cury, F.L., and Kassouf, W.

Abstract

L’intérêt de l’irradiation des ganglions lymphatiques pelviens est débattu pour les patients atteints d’un cancer de la vessie infiltrant le muscle (TVIM) bénéficiant d’une radiothérapie (RT) à visée curative. L’objectif de notre étude était de comparer les résultats oncologiques entre la RT de la vessie seule (VO) et la RT vessie et pelvis (WP) à l’aide d’une base de données collaborative multicentrique canadienne.

Published
2024
Full Text
View/download PDF

19. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis

Author

Kamat, A.M., Lerner, S.P., O'Donnell, M., Georgieva, M.V., Yang, M., Inman, B.A., Kassouf, W., Boorjian, S.A., Tyson, M.D., Kulkarni, G.S., Chang, S.S., Konety, B.R., Svatek, R.S., Balar, A., Witjes, J.A., Kamat, A.M., Lerner, S.P., O'Donnell, M., Georgieva, M.V., Yang, M., Inman, B.A., Kassouf, W., Boorjian, S.A., Tyson, M.D., Kulkarni, G.S., Chang, S.S., Konety, B.R., Svatek, R.S., Balar, A., and Witjes, J.A.

Abstract

Item does not contain fulltext, CONTEXT: Currently, there is no standard of care for patients with non-muscle-invasive bladder cancer (NMIBC) who recur despite bacillus Calmette-Guerin (BCG) therapy. Although radical cystectomy is recommended, many patients decline to undergo or are ineligible to receive it. Multiple agents are being investigated for use in this patient population. OBJECTIVE: To systematically synthesize and describe the efficacy and safety of current and emerging treatments for NMIBC patients after treatment with BCG. EVIDENCE ACQUISITION: A systematic literature search of MEDLINE, Embase, and the Cochrane Controlled Register of Trials (period limited to January 2007-June 2019) was performed. Abstracts and presentations from major conference proceedings were also reviewed. Randomized controlled trials were assessed using the Cochrane risk of bias tool. Data for single-arm trials were pooled using a random-effect meta-analysis with the proportions approach. Trials were grouped based on the minimum number of prior BCG courses required before enrollment and further stratified based on the proportion of patients with carcinoma in situ (CIS). EVIDENCE SYNTHESIS: Thirty publications were identified with data from 23 trials for meta-analysis, of which 17 were single arm. Efficacy and safety outcomes varied widely across studies. Heterogeneity across trials was reduced in subgroup analyses. The pooled 12-mo response rates were 24% (95% confidence interval [CI]: 16-32%) for trials with two or more prior BCG courses and 36% (95% CI: 25-47%) for those with one or more prior BCG courses. In a subgroup analysis, inclusion of >/=50% of patients with CIS was associated with a lower response. CONCLUSIONS: The variability in efficacy and safety outcomes highlights the need for consistent endpoint reporting and patient population definitions. With promising emerging treatments currently in development, efficacious and safe therapeutic options are urgently needed for this difficult-to-treat patient

Published
2020

22. Étude de phase I évaluant l’administration concomitante de l’atezolizumab à la thérapie trimodale pour patients atteints d’un cancer de vessie localisé infiltrant le muscle

Author

Marcq, G., primary, Souhami, L., additional, Cury, F., additional, Salimi, A., additional, Aprikian, A., additional, Tanguay, S., additional, Vanhuyse, M., additional, Rajan, R., additional, Brimo, F., additional, Mansure, J., additional, and Kassouf, W., additional

Published
2020
Full Text
View/download PDF

24. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium

Author

Mir, C., primary, Marchioni, M., additional, Zargar, H., additional, Zargar-Shoshtari, K., additional, Fairey, A.S., additional, Mertens, L.S., additional, Dinney, C.P., additional, Krabbe, L., additional, Cookson, M.S., additional, Jacobsen, N., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Xylinas, E., additional, McGrath, J.S., additional, Kassouf, W., additional, Dell’Era, M.A., additional, Sridhar, S.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A.J., additional, Shah, J.B., additional, van Rhijn, B.W., additional, Spiess, P.E., additional, Daneshmand, S., additional, and Black, P.C., additional

Published
2020
Full Text
View/download PDF

25. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer patients without hydronephrosis: results from a large multicenter cohort study

Author

Soria, F., primary, Giordano, A., additional, Black, P., additional, Fairey, A., additional, Cookson, M., additional, Yu, E., additional, Kassouf, W., additional, Dall’Era, M., additional, Sridhar, S., additional, McGrath, J., additional, Wright, J., additional, Thorpe, A., additional, Morgan, T., additional, Daneshmand, S., additional, Holzbeierlein, J., additional, Bivalacqua, T., additional, North, S., additional, Barocas, D., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A., additional, Shah, J., additional, van Rhijn, B., additional, Spiess, P., additional, Shariat, S., additional, and Gontero, P., additional

Published
2020
Full Text
View/download PDF

26. Reporting radical cystectomy outcomes following implementation of Enhanced Recovery after Surgery (ERAS) protocols: A systematic review and individual patient data meta-analysis

Author

Williams, S., primary, Cumberbatch, M., additional, Kamat, A., additional, Kerr, P., additional, Mcgrath, J., additional, Djaladat, H., additional, Collins, J., additional, Jubber, I., additional, Packiam, V., additional, Steinberg, G., additional, Lee, E., additional, Kassouf, W., additional, Black, P., additional, Cerantola, Y., additional, Catto, J., additional, and Daneshmand, S., additional

Published
2020
Full Text
View/download PDF

27. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: Results of an international consortium

Author

Marchioni, M., primary, Mir, M.C., additional, Zargar, H., additional, Grivas, P., additional, Dall’era, M.A.D., additional, Spiess, P.E.S., additional, Van Rhijn, B.W., additional, Lotan, Y., additional, Bivalacqua, T.J., additional, Holzbeierlein, J.M., additional, Thorpe, A., additional, Yu, E., additional, Shariat, S.F., additional, Kassouf, W., additional, Barocas, D.A., additional, Daneshmand, S., additional, Dinney, C.P., additional, Mcgrath, J.S., additional, Sridhar, S.S., additional, Wright, J., additional, North, S., additional, Stephenson, A.J, additional, Xylinas, E., additional, and Black, P., additional

Published
2020
Full Text
View/download PDF

28. Abstract A26: Immune profiling and organoids generation of a rare case of prostate cancer liver metastasis

Author

Le Page, Aurélie Y., primary, de Polo, Anna, additional, Guérard, K-P, additional, Lazaris, A., additional, Petrillo, S.K., additional, Ebrahimizadeh, W., additional, Tabariès, S., additional, Shinde-Jadhav, S., additional, Feldiorean, A., additional, Boufaeid, N., additional, Kassouf, W., additional, Piccirillo, C., additional, Siegel, P.M., additional, Aprikian, A., additional, Gregorieff, A., additional, Lapointe, J., additional, Metrakos, P., additional, and Labbé, D.P., additional

Published
2020
Full Text
View/download PDF

29. Reply by Authors

Author

Lotan, Y., primary, Inman, B. A., additional, Davis, L. G., additional, Kassouf, W., additional, Messing, E., additional, Daneshmand, S., additional, Canter, D., additional, Marble, H. T., additional, Joseph, A. M., additional, Jewell, S., additional, and Boorjian, S. A., additional

Published
2020
Full Text
View/download PDF

31. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

Author

Monteiro, L.L., Witjes, J.A., Agarwal, P.K., Anderson, C.B., Bivalacqua, T.J., Bochner, B.H., Boormans, J.L., Chang, S.S., Dominguez-Escrig, J.L., McKiernan, J.M., Dinney, C., Godoy, G., Kulkarni, G.S., Mariappan, P., O'Donnell, M.A., Rentsch, C.A., Shah, J.B., Solsona, E., Svatek, R.S., Heijden, A.G. van der, Valenberg, F.J.P. van, Kassouf, W., Monteiro, L.L., Witjes, J.A., Agarwal, P.K., Anderson, C.B., Bivalacqua, T.J., Bochner, B.H., Boormans, J.L., Chang, S.S., Dominguez-Escrig, J.L., McKiernan, J.M., Dinney, C., Godoy, G., Kulkarni, G.S., Mariappan, P., O'Donnell, M.A., Rentsch, C.A., Shah, J.B., Solsona, E., Svatek, R.S., Heijden, A.G. van der, Valenberg, F.J.P. van, and Kassouf, W.

Abstract

Item does not contain fulltext, PURPOSE: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC). METHODS: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma in situ [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC. RESULTS: Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies. CONCLUSION: NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk stratification are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC.

Published
2019

36. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Author

Vasdev, N., primary, Zargar, H., additional, Noël, J. P., additional, Veeratterapillay, R., additional, Fairey, A. S., additional, Mertens, L. S., additional, Dinney, C. P., additional, Mir, M. C., additional, Krabbe, L. M., additional, Cookson, M. S., additional, Jacobsen, N. E., additional, Gandhi, N. M., additional, Griffin, J., additional, Montgomery, J. S., additional, Yu, E. Y., additional, Xylinas, E., additional, Campain, N. J., additional, Kassouf, W., additional, Dall’Era, M. A., additional, Seah, J. A., additional, Ercole, C. E., additional, Horenblas, S., additional, Sridhar, S. S., additional, McGrath, J. S., additional, Aning, J., additional, Shariat, S. F., additional, Wright, J. L., additional, Morgan, T. M., additional, Bivalacqua, T. J., additional, North, S., additional, Barocas, D. A., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A. J., additional, Shah, J. B., additional, van Rhijn, B. W., additional, Daneshmand, S., additional, Spiess, P. E., additional, Holzbeierlein, J. M., additional, Thorpe, A., additional, and Black, P. C., additional

Published
2018
Full Text
View/download PDF

37. Validation of pre-treatment risk stratification parameters according to EAU Guidelines on upper tract urothelial carcinoma (UTUC)

Author

Förster, B., primary, Matin, S., additional, Seisen, T., additional, Xylinas, E., additional, Kimura, S., additional, Monteiro, L., additional, Azizi, M., additional, Bandini, M., additional, Clinton, T., additional, Hendricksen, K., additional, Ku, J., additional, Grabbert, M., additional, Czech, A., additional, Mathieu, R., additional, Muilwijk, T., additional, Krabbe, L.-M., additional, Rouprêt, M., additional, Briganti, A., additional, Heidenreich, A., additional, Pycha, A., additional, Autorino, R., additional, Anele, U., additional, Egawa, S., additional, Spiess, P., additional, Kassouf, W., additional, and Shariat, S., additional

Published
2018
Full Text
View/download PDF

38. Value of repeated ureterorenoscopy within the first 3 months after endoscopic treatment in upper tract urothelial carcinoma (UTUC)

Author

Förster, B., primary, Muilwijk, T., additional, Xylinas, E., additional, Seisen, T., additional, Monteiro, L., additional, Bandini, M., additional, Schweitzer, D., additional, D’Andrea, D., additional, Bianchi, M., additional, Abufaraj, M., additional, Hendricksen, K., additional, Joniau, S., additional, Rouprêt, M., additional, Briganti, A., additional, Autorino, R., additional, Anele, U., additional, Kassouf, W., additional, John, H., additional, Van Rhijn, B., additional, Colin, P., additional, and Shariat, S., additional

Published
2018
Full Text
View/download PDF

39. SC287 - Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium

Author

Mir, C., Marchioni, M., Zargar, H., Zargar-Shoshtari, K., Fairey, A.S., Mertens, L.S., Dinney, C.P., Krabbe, L., Cookson, M.S., Jacobsen, N., Griffin, J., Montgomery, J.S., Vasdev, N., Yu, E.Y., Xylinas, E., McGrath, J.S., Kassouf, W., Dell’Era, M.A., Sridhar, S.S., Aning, J., Shariat, S.F., Wright, J.L., Thorpe, A.C., Morgan, T.M., Holzbeierlein, J.M., Bivalacqua, T.J., North, S., Barocas, D.A., Lotan, Y., Grivas, P., Stephenson, A.J., Shah, J.B., van Rhijn, B.W., Spiess, P.E., Daneshmand, S., and Black, P.C.

Published
2020
Full Text
View/download PDF

40. SC79 - Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer patients without hydronephrosis: results from a large multicenter cohort study

Author

Soria, F., Giordano, A., Black, P., Fairey, A., Cookson, M., Yu, E., Kassouf, W., Dall’Era, M., Sridhar, S., McGrath, J., Wright, J., Thorpe, A., Morgan, T., Daneshmand, S., Holzbeierlein, J., Bivalacqua, T., North, S., Barocas, D., Lotan, Y., Grivas, P., Stephenson, A., Shah, J., van Rhijn, B., Spiess, P., Shariat, S., and Gontero, P.

Published
2020
Full Text
View/download PDF

41. PT406 - Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer patients without hydronephrosis: Results from a large multicenter cohort study

Author

Soria, F., Black, P.C., Fairey, A.S., Cookson, M.S., Yu, E.Y., Kassouf, W., Dall’era, M.A., Sridhar, S.S., Mcgrath, J.S., Wright, J.L., Thorpe, A.C., Morgan, T.M., Daneshmand, S., Holzbeierlein, J.M., Bivalacqua, T.J., North, S., Barocas, D.A., Lotan, Y., Grivas, P., Stephenson, A.J., Shah, J.B., Van Rhijn, B.W., Spiess, P.E., Shariat, S.F., and Gontero, P.

Published
2020
Full Text
View/download PDF

43. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations

Author

Kassouf, W, Traboulsi, SL, Schmitz-Drager, B, Palou, J, Witjes, JA, van Rhijn, BWG, Grossman, HB, Kiemeney, LA, Goebell, PJ, and Kamat, AM

Subjects
Risk, Urine markers, Surveillance, Recurrence, Follow-up, Prediction
Abstract

Objective: Non-muscle-invasive bladder cancer (NMIBC) comprises a wide spectrum of tumors with different behaviors and prognoses. It follows that the surveillance for these tumors should be adapted according to the risks of recurrence and progression and should be dynamic in design. Methods and materials: Medline search was conducted from 1980 to 2016 using a combination of MeSH and keyword terms. The highest available evidence was reviewed to define different risk groups in NMIBC. The performance of different follow-up tools such as urine cytology, cystoscopy, and upper tract imaging in detecting bladder carcinoma was assessed. Different commercially available urinary markers were investigated to determine whether such markers would contribute to the surveillance of patients with NMIBC. A follow-up scheme based on the early evidence is proposed. Results: A risk-based approach is paramount. Cystoscopy and cytology are recommended to be done at 3 months following transurethral resection of bladder tumor. For low-risk tumors, annual cystoscopy alone is sufficient; no upper tract evaluations or cytology is needed except at diagnosis. High-risk tumors should be followed up with a more intense schedule: cystoscopy every 3 months for 2 years, 6 months for 2 years, and then annually, with cytology at frequent intervals, and imaging for upper tract evaluation at 1 year and then every 2 years. Intermediate-risk tumors should be subclassified as per the International Bladder Cancer Group recommendations and when associated with 3 or more of the following findings (multiple tumors, size >= 3cm, early recurrence 1 per year) then a surveillance strategy similar to that of high risk should be followed. Several urine markers were more sensitive than cytology in the detection of NMIBC; however, these tests are still costly, require specialized laboratories, and do not replace cystoscopy. Until better and cheaper markers are available, their routine use has not been integrated in the follow-up recommendation of current guidelines. Conclusions: Surveillance of NMIBC should follow a risk-adapted approach, with a combination of cystoscopy, cytology, and upper tract imaging. The aim of this approach is to minimize the therapeutic burden of a disease with high recurrence rates without missing progressing tumors. When designing a diagnostic pathway, first-line diagnostic imaging tests should have high sensitivity to ensure disease positives are included in the test population for further investigation. Second-line investigations should be highly specific, to ensure false-positives are minimized. (C) 2016 Elsevier Inc. All rights reserved

Published
2016

44. Validation externe d’un nomogramme de prédiction des complications après néphro-urétérectomie totale

Author

Patard, P., primary, Xylinas, E., additional, Anract, J., additional, Chang, P., additional, Deway, L., additional, Wagner, A., additional, Petros, F., additional, Matin, S., additional, Tobert, C., additional, Tracy, C., additional, Monteiro, L., additional, Kassouf, W., additional, Raman, J., additional, Roumiguié, M., additional, Shariat, S., additional, Klatte, T., additional, and Zerbib, M., additional

Published
2017
Full Text
View/download PDF

48. Does associated CIS with MIBC impact on neoadjuvant chemotherapy? Results of an International consortium

Author

Vasdev, N., primary, Zagar, H., additional, Noel, J., additional, Suleyman, N., additional, Thorpe, A., additional, Mir, M.C., additional, Ercole, C.E., additional, Zargar-Shoshtari, K., additional, Fairey, A.S., additional, Mertens, L.S., additional, Dinney, C.P., additional, Krabbe, L.M., additional, Cookson, M.S., additional, Jacobsen, N.E., additional, Gandhi, N.M., additional, Griffin, J., additional, Montgomery, J.S., additional, Yu, E.Y., additional, Xylinas, E., additional, Campain, N.J., additional, Veeraterpillay, R., additional, Kassouf, W., additional, Dall’Era, M.A., additional, Seah, J.A., additional, Horenblas, S., additional, Sridhar, S.S., additional, McGrath, J.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Garcia, J.A., additional, Grivas, P., additional, Shah, J.B., additional, Van Rhijn, B.W., additional, Daneshmand, S., additional, Spiess, P.E., additional, Li, J., additional, Stephenson, A.J., additional, and Black, P., additional

Published
2017
Full Text
View/download PDF

49. Nomogramm zur Prädiktion von rezidivfreiem Überleben bei Patienten mit einem high-grade Urothelkarzinom des oberen Harntraktes nach Operation

Author

Krabbe, L.-M., Eminaga, O., Boegemann, M., Shariat, S., Lotan, Y., Sagalowsky, A., Raman, J., Wood, C., Weizer, A., Roscigno, M., Montorsi, F., Bolenz, C., Remzi, M., Bensalah, K., Kassouf, W., and Margulis, V.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Nomogramme können zur individuellen Therapieplanung sowie auch besseren Information von Patienten genutzt werden. Wir stellen ein Nomogramm zur Prädiktion des rezidivfreien Überlebens (RFÜ) von Patienten mit high-grade Urothelkarzinom des oberen Harntraktes (UTUC) [for full text, please go to the a.m. URL], 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2015

50. Prognostische Bedeutung eines früheren Urothelkarzinoms der Harblase bei Patienten mit Urothelkarzinom des oberen Harntrakts

Author

Nuhn, P, Novara, G, Aziz, A, Seitz, C, Gupta, A, Matsumoto, K, Kassouf, W, Walton, TJ, Fritsche, HM, Tritschler, S, Martínez-Salamanca, JI, Ficarra, V, Karakiewicz, PI, Mazzoleni, G, Shariat, SF, Stief, SC, and Bastian, P

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Patienten mit Urothelkarzinom (UC) entwickeln häufig multifokale metachrone Tumoren im gesamten Harntrakt. In der vorliegenden Studie evaluierten wir die prognostische Bedeutung eines früheren UC der Harnblase (UCB) bei Patienten mit UC des oberen Harntrakts (UTUC) in einer [for full text, please go to the a.m. URL], 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results